BMJ Global Health

BMJ Global Health is an open access journal from BMJ Publishing Group that launched in 2016 and publishes research, analysis and practice on health policy, health systems and equity worldwide, with a 2025 Journal Impact Factor of 5.8.《BMJ 全球健康》（BMJ Global Health）是（BMJ Publishing Group）旗下的开放获取期刊，2016 年创刊，发表有关全球卫生政策、卫生体系与健康公平的研究、分析与实践文章，2025 年期刊影响因子为 5.8。

Scope

• The journal addresses major global health questions and controversies, with an explicit interest in low and middle income country settings.本刊聚焦重大全球卫生议题与争议，并明确关注中低收入国家的现实情境。
• Health policy and governance, health financing, and the organisation and performance of health systems are core subject areas.卫生政策与治理、卫生筹资，以及卫生体系的组织与绩效，是核心主题领域。
• Public health interventions, epidemiology and the evaluation of large scale programmes are published alongside policy analysis.公共卫生干预、流行病学以及大规模项目的评估，与政策分析并列发表。
• Global surgery, maternal and child health, infectious disease control and non-communicable disease burden all appear regularly in its pages.全球外科、妇幼健康、传染病控制与非传染性疾病负担，均常出现在本刊版面。
• Qualitative work is welcomed provided it is framed by social science theory, and mixed methods studies are explicitly encouraged.定性研究只要以社会科学理论为框架即受欢迎，混合方法研究亦被明确鼓励。
• A separate article type, Global health in practice, reports field implementation experience at community, district or national level.独立的「全球卫生实践」栏目，报道社区、地区或国家层面的实地实施经验。
• Research is expected to connect its findings to comparable studies, and equity and inclusion in the research workforce are treated as editorial concerns.研究须将发现与同类研究相连接，研究队伍的公平与包容也被视为编辑层面应予关切的问题。

History

• The journal was established in 2016 as BMJ's dedicated outlet for global health, extending the group's long standing general medical publishing into a field specific title.本刊于 2016 年创办，是（BMJ）专为全球卫生设立的刊物，把该集团长期的综合医学出版延伸为领域专刊。
• It was launched as an online only, fully open access title, so it never carried a subscription paywall or a print edition.创刊即为纯在线、完全开放获取期刊，因此从未设置订阅付费墙，也没有纸本版。
• The default licence is CC BY-NC, with CC BY available for authors who pay the additional charge, a model intended to keep reuse rights broad.默认许可为 CC BY-NC，作者支付额外费用后可选择 CC BY，这一模式意在保持较宽泛的再利用权利。
• Tobacco industry funding is grounds for rejection, and financial associations between authors and the tobacco industry are treated in the same way.烟草业资助构成拒稿理由，作者与烟草业的财务关联亦按同样标准处理。
• The journal requires a reflexivity statement whenever authors from high income and low or middle income countries collaborate on a study.当高收入国家与中低收入国家作者合作开展研究时，本刊要求提交反身性声明。
• The 2025 impact factor is 5.8, against 6.1 in 2024 and 8.056 in 2022, with a CiteScore of 9.3 and an acceptance rate of about 15 percent.2025 年影响因子为 5.8，2024 年为 6.1，2022 年为 8.056，CiteScore 为 9.3，录用率约 15%。

Editors

• Mark G. Shrime, a lecturer in global health and social medicine at Harvard Medical School, is editor-in-chief and works on decision science and surgical delivery in low resource settings.哈佛医学院全球卫生与社会科学讲师 Mark G. Shrime 担任主编，研究决策科学与资源匮乏环境下的外科服务提供。
• Helen Surana and Fiona Godlee serve as senior editors, and the associate editor group is deliberately weighted towards institutions in Africa, South Asia and Latin America.Helen Surana 与 Fiona Godlee 担任高级编辑，助理编辑团队有意向非洲、南亚与拉丁美洲的机构倾斜。
• Associate editors are listed with their institutions and specialties, ranging from global surgery and health economics to spatial epidemiology and biostatistics.助理编辑均列出所属机构与专长，覆盖从全球外科、卫生经济学到空间流行病学与生物统计的范围。
• An editorial advisory board of about thirty members drawn from universities, foundations and multilateral bodies provides strategic advice.由高校、基金会与多边机构人士组成的约三十人编辑顾问委员会提供战略性建议。
• Review is single anonymised, referee names are withheld from authors, and original research normally requires two external reports before acceptance.评审采用单盲方式，审稿人姓名对作者保密，原创研究通常需两份外部审稿报告方可录用。
• Every published article is labelled as solicited or unsolicited and as internally or externally reviewed, and ORCID identifiers are mandatory at submission.每篇发表文章均标注约稿或自由来稿、内部或外部评审，投稿时作者必须提供 ORCID 标识。
• The median time to a first decision with review is 107 days, and all research papers must carry a data availability statement.带评审的首次决定中位时间为 107 天，所有研究论文必须附数据可用性声明。